RedHill Biopharma Ltd. (RDHL)

NASDAQ: RDHL · Real-Time Price · USD
2.790
+0.040 (1.45%)
At close: Mar 28, 2025, 4:00 PM
2.700
-0.090 (-3.23%)
After-hours: Mar 28, 2025, 7:58 PM EDT
1.45%
Market Cap 3.57M
Revenue (ttm) 3.71M
Net Income (ttm) -30.17M
Shares Out 1.28M
EPS (ttm) -38.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,078
Open 2.710
Previous Close 2.750
Day's Range 2.660 - 2.800
52-Week Range 2.470 - 20.280
Beta 3.83
Analysts n/a
Price Target n/a
Earnings Date Apr 11, 2025

About RDHL

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiat... [Read more]

Sector Healthcare
Founded 2009
Employees 53
Stock Exchange NASDAQ
Ticker Symbol RDHL
Full Company Profile

Financial Performance

Financial Statements

News

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill plans to submit UK MAA 1  for Talicia for H. pylori infection, using MHRA's 2  new fast-track approval process, referencing FDA approval, with potential UK approval in Q4/25 Listed by ACG 3  C...

12 days ago - PRNewsWire

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn's Disease (CD) patients who are all MAP-positive, and will correlate mucosal healing with MAP2 infection...

18 days ago - PRNewsWire

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum The update covers: The recent out-licensing of RHB-102 [1] to Hyloris (Euronext...

4 weeks ago - PRNewsWire

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

- Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in return for exclusive rights to develop and com...

4 weeks ago - PRNewsWire

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer (mC...

7 weeks ago - PRNewsWire

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or aut...

2 months ago - PRNewsWire

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radi...

3 months ago - PRNewsWire

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill has been awarded a judgment of approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd The Court dismissed the en...

4 months ago - PRNewsWire

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill has been selected to provide a presentation to further elaborate on opaganib's potential to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Radi...

5 months ago - PRNewsWire

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine ...

5 months ago - PRNewsWire

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical countermeasure (MCM) to treat Ebola virus disease (E...

5 months ago - PRNewsWire

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Medi-Cal, California's Medicaid healthcare program, and RedHill have renewed their contract to maintain Talicia's first-line position on the Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) wit...

6 months ago - PRNewsWire

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-...

6 months ago - PRNewsWire

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

First new American College of Gastroenterology (ACG) Clinical Guideline [1] for H. pylori infection since Talicia's approval lists Talicia as an empirically prescribed first-line option Talicia's conv...

7 months ago - PRNewsWire

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

TEL AVIV, Israel and RALEIGH, N.C. , Sept. 5, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.

7 months ago - PRNewsWire

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement in...

7 months ago - PRNewsWire

RedHill Biopharma Announces First Half 2024 Business Highlights

A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following   the Termination Agreement with Movantik Acquisition Co. and others : Executing on...

7 months ago - PRNewsWire

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of all childhood cancer cases and 15% of pedi...

7 months ago - PRNewsWire

Talicia® Launched in the United Arab Emirates

RedHill's Talicia, the first approved low-dose rifabutin-containing all-in-one combination treatment for H. pylori, is now available on prescription to treat adults with H.

7 months ago - PRNewsWire

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

On Monday, RedHill Biopharma Ltd. RDHL released results from multiple  in vivo studies, undertaken by RedHill's partner, Apogee Biotechnology Corporation.

7 months ago - Benzinga

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034 [1]  – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk's Ozempic® and Wegov...

7 months ago - PRNewsWire

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

TEL AVIV, Israel and RALEIGH, N.C. , Aug. 16, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.

8 months ago - PRNewsWire

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Newly published in the peer-reviewed journal Antibiotics, the 331-patient Phase 3 Crohn's disease study data shows the primary endpoint of clinical remission at week 26 was achieved, with high statist...

8 months ago - PRNewsWire

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing ...

8 months ago - PRNewsWire

RedHill Biopharma Terminates License Agreement for Aemcolo®

TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual de...

9 months ago - PRNewsWire